NEWS & ANALYSIS · HEALTHCARE INVESTOR MAGAZINE

UK Healthcare Investment News

Independent reporting on M&A deals, funding rounds, regulatory developments and market intelligence across UK healthcare — covering alternative healthcare investments, specialty pharma, medical cannabis, life sciences and all nine healthcare sectors.

BROWSE BY TAG:

Snoop Dogg's Casa Verde Capital Backs UK Medical Cannabis Clinic Mamedica with £4.5m

Simon Jones, Deputy Editor · June 2026

US-based venture capital firm Casa Verde Capital, co-founded by rapper Snoop Dogg, has invested £4.5 million in Mamedica — the UK's leading medical cannabis clinic — in the largest fundraising in the UK medical cannabis and alternative healthcare investment sector to date.

Read the full story →

British Business Bank and Apposite Capital £100m MedTech and Medicines Fund

NEWS · ALTERNATIVE HEALTHCARE INVESTMENTS

EXTERNAL →

Alternative Healthcare InvestmentsPrivate EquityLife Sciences

British Business Bank and Apposite Capital Launch £100m MedTech and Medicines Fund

Source: Med-Tech Insights · April 2026

The British Business Bank has committed cornerstone capital to a new £100 million fund called Apposite Healthcare Growth I, managed by Apposite Capital, a specialist healthcare and life sciences investor. The fund will invest in innovative UK companies across medical products, diagnostics, life sciences tools, digital health and pharmaceutical outsourcing services — addressing the shortage of scale-up capital for UK life sciences companies approaching a growth inflection point.

Read at Med-Tech Insights →

NEWS · SPECIALTY PHARMA

EXTERNAL →

Specialty PharmaM&ALife Sciences

US-UK Pharma Trade Deal Secures Zero Tariffs on UK Drug Exports for Three Years

Source: Osborne Clarke · April 2026

The US and UK governments announced a landmark deal on pharmaceutical trade and pricing on 2 April 2026, securing zero tariffs on UK pharmaceutical exports for at least three years. The agreement — building on the US-UK Economic Prosperity Deal agreed in May 2025 — also includes structural reforms to NHS medicines pricing and NICE evaluation aimed at improving patient access to medicines, and a pathway toward regulatory alignment for medical devices. It forms part of the UK government's life sciences sector plan, backed by over £2 billion of investment.

Read at Osborne Clarke →

NEWS · MEDICAL CANNABIS

EXTERNAL →

Medical CannabisAlternative Healthcare Investments

UK Medical Cannabis Market Approaching £1bn Valuation as Patient Numbers Near 100,000

Source: London Business Magazine · January 2026

The UK medical cannabis sector is expected to grow around 10% per year over the next five years. Patient numbers are approaching 100,000 — with the sector remaining far below its potential given that only 0.01–0.02% of UK residents have tried a medical cannabis prescription compared to 1–2% in comparable markets including Germany, the US and Canada. The first UK medical cannabis grower licensed to supply clinics for direct patient treatment began doing so in 2025, and investment into UK clinics and cultivation infrastructure accelerated throughout the year.

Read at London Business Magazine →

NEWS · VENTURE CAPITAL

EXTERNAL →

Venture CapitalLife Sciences

UK Biotech VC Rises 17% to £516m in Q1 2026 as Deal Count Jumps 60% Year-on-Year

Source: BIA (BioIndustry Association) · April 2026

UK biotech companies raised £516 million in venture capital in Q1 2026, representing a 17% increase from £442 million in Q4 2025. Deal activity rose to 24 transactions — up 60% from 15 deals in Q1 2025 — indicating a broader, more distributed funding environment compared to the large-round concentration of Q1 2025. The largest raise of the quarter was by Avacta Life Sciences, which secured £10 million to advance its clinical pipeline including oncology programmes. The increase was accompanied by broader distribution of investment across funding stages, signalling a more active and diversified environment for UK biotechs.

Read at BIA →

UK Healthcare and Pharma Services M&A Q1 2026

NEWS · PRIVATE EQUITY

EXTERNAL →

Private EquityM&A

UK Healthcare and Pharma Services M&A Surges 37% in Q1 2026 — PE Deals Up 43%

Source: Grant Thornton UK · Spring 2026

UK healthcare and pharma services M&A recorded 114 deals in Q1 2026 — a 37% uplift on the same period in 2025 — according to Grant Thornton's Spring 2026 review. Private equity and venture capital-backed transactions rose 43% year-on-year, driven by the sector's defensive resilience and structural growth characteristics. Key themes included diversification away from NHS dependency, continued appetite for niche specialist assets commanding high multiples, and PE interest in listed healthcare companies. Deals spanned medtech, pharma services, clinical services and social care.

Read at Grant Thornton →

Eli Lilly acquires Centessa Pharmaceuticals

NEWS · LIFE SCIENCES

EXTERNAL →

Life SciencesM&A

Eli Lilly Acquires UK Neuroscience Company Centessa Pharmaceuticals for Up to $7.8bn

Source: HealthCare MEA · April 2026

Eli Lilly has agreed to acquire UK-based neuroscience company Centessa Pharmaceuticals in a deal valued at up to $7.8 billion, paying $38 per share — a 37% premium to the NASDAQ closing price. Centessa shareholders will also receive contingent value rights of $9 per share, worth up to $1.5 billion, subject to regulatory milestones for lead candidate cleminorexton, a treatment for excessive daytime sleepiness and narcolepsy. The acquisition adds to a string of high-value agreements Lilly has pursued in early 2026, including a $2.4 billion deal with Orna Therapeutics and an $8.8 billion collaboration with Innovent.

Read at HealthCare MEA →

NEWS · M&A

EXTERNAL →

M&APrivate Equity

UK Healthcare M&A Reaches 280 Deals in 2025 — Outperforming Wider Market by 10–15 Percentage Points

Source: Heligan Group via Home Care Insight · February 2026

UK healthcare M&A activity totalled 280 announced or completed deals in 2025 — broadly flat year-on-year — while dealmaking across most UK sectors declined by 10–15%, according to Heligan Group's annual review. Health and Social Care accounted for 47% of deal volume. Strategic buyers represented 83% of transactions. Inbound transactions accounted for 24% of activity, with the US the largest source of cross-border investment. PE remained active on bolt-ons despite entering 2026 with significant dry powder. The sector's defensive and structurally supported characteristics drove continued outperformance against the wider M&A market.

Read at Home Care Insight →

Royal London Asset Management healthcare REIT

NEWS · HEALTHCARE REAL ESTATE

EXTERNAL →

Healthcare Real EstateM&A

Royal London Asset Management Launches £1bn Healthcare REIT to Scale UK Care Infrastructure Investment

Source: Investors in Healthcare / Real Assets · October 2025

Royal London Asset Management Property has launched a UK healthcare real estate investment trust, which it plans to grow to £1 billion in value. The firm has already deployed £350 million in healthcare property assets since early 2022, and in mid-2025 brought sector specialists Shoreline Partners in-house as part of its £1 billion ambition. RLAM Property said the REIT structure will provide a more competitive and internationally recognised investment vehicle to attract third-party capital, execute forward funding deals and acquire corporate entities. The launch reflects growing domestic investor appetite for UK healthcare real estate alongside the dominant US REIT capital that deployed £12 billion+ into the sector in 2025.

Read at Investors in Healthcare →

Smith & Nephew acquires Integrity Orthopaedics

NEWS · MEDTECH

EXTERNAL →

MedTechM&A

Smith & Nephew Acquires Integrity Orthopaedics for £450m in Q1 2026 Strategic Bolt-On

Source: Business Sale Report / Manufacturing Chemist · Q1 2026

FTSE 100 medical technology company Smith & Nephew completed a £450 million takeover of Integrity Orthopaedics in Q1 2026, reinforcing its orthopaedics portfolio through targeted inorganic growth. The acquisition is part of Smith & Nephew's ongoing programme of bolt-on deals to strengthen its position in high-growth orthopaedic sub-segments. The deal took place alongside GSK's £1.7 billion acquisition of RAPT Therapeutics and Sovereign Capital Partners' acquisition of Apollo Home Healthcare as the three most significant UK-connected healthcare transactions of Q1 2026, according to the Heligan Group quarterly review.

Read at Manufacturing Chemist →

NHS Shared Business Services £900m AI framework

NEWS · HCIT

EXTERNAL →

HCITMedTechDiagnostics

NHS Shared Business Services Launches £900m Healthcare AI Solutions Procurement Framework

Source: Digital Health News · May 2026

NHS Shared Business Services launched a £900 million framework agreement on 11 May 2026 to support procurement of AI technologies across the NHS and wider public sector. The Healthcare AI Solutions framework covers diagnostics, predictive analytics, operational efficiency, robotics and consultancy services, providing NHS organisations with a national procurement route for AI technologies. The framework's launch — significantly expanded in value following supplier consultations — signals the scale of NHS commitment to AI-enabled healthcare delivery under the government's 10 Year Health Plan.

Read at Digital Health →

NEWS · ANIMAL HEALTH

EXTERNAL →

Animal HealthVenture Capital

Animalcare Group Reports 20% Revenue Growth in 2025 Following Randlab Acquisition and Asia-Pacific Expansion

Source: Hargreaves Lansdown / Sharecast · January 2026

AIM-listed Animalcare Group reported revenue growth of 20% year-on-year to £89.1 million in 2025, reflecting successful integration of the Randlab acquisition alongside continued organic growth and new product development. The veterinary medicines group strengthened its Asia-Pacific presence through a 25% strategic equity investment in Australia-based InVetro, and signed a licence agreement with 272Bio to access half-life extension technology for equine biologics. Animalcare said it plans to invest approximately 5% of revenue annually in innovation from 2026 — with five key R&D projects currently in progress including a VHH NGF antibody programme for companion animal pain.

Read at Hargreaves Lansdown →

NEWS · DIAGNOSTICS

EXTERNAL →

DiagnosticsMedTechHCIT

UK Government Invests £28.1m in NHS AI Diagnostics — Including £20m to Roll Out AI Chest X-Ray to Every NHS Trust by 2029

Source: NIHR / DHSC · June 2026

The UK government has announced £28.1 million of investment in NHS AI diagnostic tools, including £20 million to extend AI-assisted chest X-ray technology to every NHS Trust in England by 2029. The software — which helps radiologists identify abnormalities more quickly — is already deployed in around half of NHS Trusts and has supported faster diagnoses for more than four million patients. An additional £8.1 million through NIHR will fund development and evaluation of six new AI and digital health technologies across 12 NHS Trusts, covering CT scans, ECGs and X-rays for conditions including heart failure, stroke, lung infections and lung cancer.

Read at Innovation News Network →

NEWS · MEDTECH

EXTERNAL →

MedTechHCIT

Med-Tech Expo 2026: UK MedTech Community Unites at the NEC as Value-Based Procurement Arrives

Simon Jones, Deputy Editor · June 2026

Med-Tech Expo 2026 at Birmingham's NEC drew widespread acclaim from exhibitors and delegates as the UK medical device industry gathered under one roof for two days of live demonstrations, innovation showcases and policy debate. The standout moment came on the Insights Stage, where NHS Supply Chain formally confirmed the rollout of Value-Based Procurement — with a mandatory 40/60 scoring split capping whole-life cost at 40% and allocating at least 60% of evaluation weighting to verified system value including clinical outcomes, patient impact and supply chain resilience. As one attendee noted: the evidence must now become procurement documentation, not key opinion leader conversation. The Start-Up Zone and NIHR PITCH Competition drew particular praise, with MedScan 3D taking the inaugural prize. Organisers confirmed the event will return to the NEC in 2027.

Read the full report at Med-Tech Insights →

NEWS · MEDTECH · INVESTMENT

EXTERNAL →

MedTechVenture CapitalInvestment

Star51 Capital Announces First Close of MedTech Ecosystem Fund Anchored by Abbott and Mayo Clinic

Simon Jones, Deputy Editor · 11 June 2026

Star51 Capital — a venture investment platform designed to bridge the gap between MedTech innovation and acquisition — has announced the first close of its inaugural fund. The close was led by Abbott and Mayo Clinic, with significant participation from senior MedTech executives, physicians and life science professionals alongside the fund's general and operating partners. Star51 invests in early and growth-stage companies spanning interventional therapies, diagnostics, monitoring and the digitalisation of healthcare across the United States, Europe and the Middle East. The fund is led by Founding Managing Partners Adam Rosenwach and Tal Wenderow — the latter having founded Corindus Vascular Robotics and steered its $1.1 billion acquisition by Siemens Healthineers. Operating Partners include Raymond W. Cohen, who has engineered over $5 billion in exit value across multiple MedTech companies, and Scott Pantel, Founder and CEO of LSI.

Read the full announcement at PR Newswire →

FesariusTherapeutics DermiSphere hydrogel dermal regeneration

NEWS · MEDTECH · INVESTMENT

EXTERNAL →

MedTechVenture CapitalDiagnostics

FesariusTherapeutics Closes Oversubscribed $20M Series A for DermiSphere™ — the First Hydrogel Dermal Regeneration Template on the US Market

Simon Jones, Deputy Editor · 10 June 2026

FesariusTherapeutics has closed an oversubscribed $20 million Series A financing round for DermiSphere™ — the first hydrogel Dermal Regeneration Template (hDRT) on the US market, FDA 510(k)-cleared in January 2025 for managing various wound types. The round was anchored by Jefferson Life Sciences and joined by Johnson & Johnson Innovation (JJDC), Empire State Development's NY Ventures and the American Society of Plastic Surgeons — the last marking its inaugural institutional investment. Proceeds will expand FesariusTherapeutics' commercial presence across US hospital systems, pursue Breakthrough Device Designation with expanded reimbursement pathways and advance the clinical trial for its OneStep procedure — placing DermiSphere™ and a skin graft in a single surgery, which has the potential to eliminate the second procedure currently required by the standard of care. The $1.6 billion US market for dermal regeneration has seen virtually no innovation in 30 years.

Read the full announcement at PR Newswire →

Baird Medical relocates global headquarters to New York City

NEWS · MEDTECH · M&A

EXTERNAL →

MedTechM&A

Baird Medical Relocates Global Headquarters to New York City to Accelerate US Commercial Expansion

Simon Jones, Deputy Editor · 9 June 2026

Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) — a market leader in minimally invasive Microwave Ablation technology — has announced the relocation of its global headquarters to New York City following the December 2025 appointment of Mark Saxton as CEO of its US subsidiary. The move follows Baird Medical's strategy to accelerate its domestic commercial footprint and provides more efficient access to the world's most sophisticated healthcare investors. Baird Medical's MWA solutions are currently utilised by over 30 prestigious US institutions including Mayo Clinic, Columbia University Medical Center, UCSF Medical Center and Weill Cornell Medical Center. The company is the market leader for thyroid microwave ablation devices in China and is rapidly expanding commercially across more than 20 countries. Chief Executive Saxton described the relocation as the next step in the company's evolution as a global MedTech company.

Read the full announcement at PR Newswire →

NEWS · MEDTECH

EXTERNAL →

MedTechLife Sciences

ProVerum Appoints Former Medtronic Vice President Jesse Litwak as Chief Financial Officer

Simon Jones, Deputy Editor · 8 June 2026

ProVerum Limited — a Dublin-based medical device company focused on minimally invasive solutions for benign prostatic hyperplasia (BPH) — has appointed Jesse Litwak as Chief Financial Officer. Litwak joins following 16 years at Medtronic, where he most recently served as Vice President of Finance and CFO for its $6 billion global Surgical business. ProVerum's FDA-approved ProVee System addresses BPH — the most common reason men seek urological care — with more than 12 million men in the United States actively managed for the condition. Litwak's appointment comes as ProVerum scales its commercial operations and expands access to the ProVee technology. CEO Paul Bateman described the hire as bringing a rare blend of experience spanning early-stage commercial companies and large, global, publicly traded MedTech organisations.

Read the full announcement at PR Newswire →

Galmed Pharmaceuticals acquires Colospan

NEWS · MEDTECH · M&A

EXTERNAL →

MedTechM&ASpecialty Pharma

Galmed Pharmaceuticals to Acquire Colospan to Create a GI-Focused MedTech Platform Targeting a $6 Billion Market

Simon Jones, Deputy Editor · 8 June 2026

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) has entered into a definitive agreement to acquire Colospan Ltd. — a commercial-stage medical device company that has developed a clinically differentiated solution to anastomotic leak complications in colorectal surgery, one of the field's most serious unmet needs. Colospan's flagship product, the CG-100 intraluminal bypass device, is a minimally invasive alternative designed to protect the anastomosis and reduce the need for a diverting stoma — a temporary abdominal opening that redirects waste to an external bag during healing. The CG-100 holds FDA Breakthrough Device Designation, CE marking under EU MDR and is currently in a US pivotal clinical trial. Under the terms of the agreement, Colospan shareholders will receive $2.5 million in cash and $2.0 million in Galmed ordinary shares at closing. Galmed plans a $6 million investment to launch Colospan's device in Germany, Austria and Switzerland during H2 2026. Colorectal cancer is the third most commonly diagnosed cancer globally, with approximately 1.9 million new cases annually.

Read the full announcement at PR Newswire →

Implantica RefluxStop Centre of Excellence at MD Anderson Madrid

NEWS · MEDTECH

EXTERNAL →

MedTechLife Sciences

Implantica Establishes 20th RefluxStop® Centre of Excellence in Spain at MD Anderson Cancer Center Madrid

Simon Jones, Deputy Editor · 9 June 2026

Implantica AG (Nasdaq First North: IMP A SDB) — the Liechtenstein-headquartered medtech company behind the RefluxStop® anti-reflux implant — has established a new RefluxStop® Centre of Excellence at MD Anderson Cancer Center Madrid-Hospiten, marking the 20th such centre in Spain. The procedure was performed by Dr. Oscar Alonso MD PhD, Head of Robotic Gastrointestinal Surgery at the facility. MD Anderson Cancer Center Madrid opened in 2000 as the first international location of the world-renowned US institution and has treated over 65,000 patients. Five-year clinical data from a multicenter prospective CE-mark trial, published in Surgical Endoscopy in 2025, demonstrated an average 90% or greater improvement in GERD-related quality-of-life scores across follow-up. Approximately 15% of the population in Spain suffer from GERD. RefluxStop® is designed to address the root cause of acid reflux by restoring the lower esophageal sphincter to its natural anatomical position — without compressing the food passageway.

Read the full announcement at PR Newswire →

Kinova launches KIMA medical robotic arm

NEWS · MEDTECH · HCIT

EXTERNAL →

MedTechHCIT

Kinova Marks 20th Anniversary with Launch of KIMA — a Next-Generation Medical Robotic Arm Built for Clinical Environments

Simon Jones, Deputy Editor · 9 June 2026

Kinova — a global leader in robotics headquartered in Boisbriand, Quebec — has marked its 20th anniversary with the official launch of KIMA, a next-generation medical robotic arm purpose-built for clinical use across applications spanning endoscopy and bronchoscopy to complex surgical interventions. The launch was unveiled at the Society of Robotic Surgery 2026 Annual Meeting. Unlike systems adapted from industrial robotics, KIMA was designed from the ground up for clinical environments — natively integrating IEC 62304 Class C software and ISO 14971 safety standards. With a 3kg payload class and a lightweight frame under 13kg, KIMA eliminates bulky control boxes, enabling medical device manufacturers to build next-generation medical systems with greater speed and flexibility. The platform is supported by technology partners including QNX, RTI, MedAcuity, MPE and Acontis. Kinova's products are designed, developed and assembled in Canada.

Read the full announcement at PR Newswire →

GT Medical Technologies GammaTile brain tumor therapy

NEWS · MEDTECH · INVESTMENT

EXTERNAL →

MedTechVenture CapitalInvestment

GT Medical Technologies Raises Oversubscribed $100M Series E Led by Viking Global to Advance GammaTile® Brain Tumor Therapy

Simon Jones, Deputy Editor · 9 June 2026

GT Medical Technologies — a medical device company dedicated to improving outcomes for patients with brain tumors — has closed an oversubscribed $100 million Series E equity financing led by new investor Viking Global Investors, which manages $52 billion in capital across public and private investments. Existing investors including MVM Partners, Gilde Healthcare, Evidity Health Capital, Medtech Venture Partners and FemHealth Ventures also participated. Proceeds will accelerate commercial and operational investments following the release of Phase 3 ROADS trial data presented at ASCO 2026, which demonstrated that GammaTile® — the company's FDA-cleared bioresorbable radiotherapy implant placed at the time of brain tumor removal surgery — reduced the risk of tumor recurrence and death at 12 months by 93% and 41% respectively versus standard of care. Twenty-four-month overall survival was 61.7% for GammaTile versus 35.7% for standard of care. The financing also supports the company's recently initiated BRIDGES randomised controlled trial in patients with newly diagnosed glioblastoma.

Read the full announcement at PR Newswire →

Veritas Aortic Solutions TVARC transcatheter aortic root

NEWS · MEDTECH · INVESTMENT

EXTERNAL →

MedTechVenture CapitalInvestment

Veritas Aortic Solutions Raises $12M Seed to Advance Non-Surgical Transcatheter Treatment of Aortic Root and Ascending Aortic Disease

Simon Jones, Deputy Editor · 1 June 2026

Veritas Aortic Solutions — the latest company to spin out of inQB8 Medical Technologies — has closed $12 million in Seed financing to advance its Transcatheter Valved Aortic Root Conduit (TVARC) through First-in-Human clinical use. The round was led by experienced MedTech angel investors with strong participation from Cedars-Sinai Intellectual Property Company and inQB8's existing investors. Aortic root and ascending aortic conditions currently carry combined mortality and morbidity rates as high as 65% under open-heart surgery — the only currently approved treatment option. The Veritas TVARC is designed as a single permanent implant combining a bioprosthetic aortic valve, ascending aortic graft and the company's proprietary Chameleon Eye™ coronary perfusion ports — delivered via a transfemoral catheter to eliminate the need for open-heart surgery. The company was co-founded by cardiac surgeon Dr. Arshad Quadri and J. Brent Ratz, whose prior collaboration produced CardiAQ Valve Technologies (acquired by Edwards Lifesciences, 2015) and MonarQ (acquired by Peijia Medical, 2021).

Read the full announcement at PR Newswire →

NEWS · MEDTECH · HCIT

EXTERNAL →

MedTechHCITDiagnostics

Rhythm AI Appoints Medtech Veteran Mike Dineen as CEO to Lead US Clinical and Commercial Expansion of STAR Apollo™ Mapping System

Simon Jones, Deputy Editor · 2 June 2026

Rhythm AI — a London-headquartered digital health company developing AI-powered software to help electrophysiologists treat atrial fibrillation more precisely — has appointed Mike Dineen as Chief Executive Officer. Dineen brings over 30 years of MedTech experience as a founder, operator and commercial leader with a proven track record across cardiovascular technologies from early development through regulatory clearance and successful acquisition, including Kalila Medical (acquired by Abbott) and roles at Maya Medical (acquired by Covidien) and Concentric Medical (acquired by Stryker). The appointment follows FDA 510(k) clearance of Rhythm AI's STAR Apollo™ Mapping System for compatibility with Johnson & Johnson's CARTO™ 3 Mapping System, adding to its existing clearance with Abbott's EnSite™ X EP System — positioning STAR Apollo across the two most widely used 3D mapping platforms in clinical practice. STAR Apollo provides a precise, patient-specific map of where atrial fibrillation originates to guide targeted ablation strategies.

Read the full announcement at PR Newswire →

Novellia raises Series A for patient-powered real-world data

NEWS · MEDTECH · HCIT · INVESTMENT

EXTERNAL →

MedTechVenture CapitalHCITInvestment

Novellia Raises $18M Series A Led by Spark Capital to Scale Patient-Powered Real-World Data Platform for Pharma

Simon Jones, Deputy Editor · 2 June 2026

Novellia — the only real-world data company built entirely on information patients choose to contribute to medical research — has raised an $18 million Series A led by Spark Capital with participation from Khosla Ventures, Acrew Capital, Bling Capital and TMV, bringing total funding to $28 million. Novellia's platform helps patients with serious and complex conditions find and unify up to 20 years of medical data from disparate hospital systems, doctors' offices and laboratories across the US within 30 seconds — giving patients a free comprehensive health record while enabling pharmaceutical companies to access deidentified, patient-consented real-world datasets for drug development. Customers include several of the top ten pharmaceutical companies, and the company has signed multiple seven-figure multi-year contracts since the Spark Series A. The $50 billion real-world data market is currently dominated by third-party brokers stitching together partial datasets from insurance claims and hospital records — a system that systematically excludes the patient as a direct data source. Novellia has also launched a patient-facing mobile app as part of this announcement.

Read the full announcement at PR Newswire →

Advanced NanoTherapies SirPlux Duo drug-coated balloon

NEWS · MEDTECH · INVESTMENT

EXTERNAL →

MedTechVenture CapitalInvestmentDiagnostics

Advanced NanoTherapies Raises $31M Series B to Advance SirPlux Duo — a Dual-Drug Nanoparticle-Coated Balloon for Vascular Disease

Simon Jones, Deputy Editor · 2 June 2026

Advanced NanoTherapies (ANT) — a clinical-stage MedTech company dedicated to improving outcomes for patients with coronary and peripheral artery disease — has closed an oversubscribed Series B financing totalling more than $31 million, co-led by an undisclosed strategic investor and S3 Ventures. ANT's lead programme, SirPlux Duo — which has received FDA Breakthrough Device Designation — defines a new category in drug-coated balloon therapy by combining two established antiproliferative agents, sirolimus and paclitaxel, delivered simultaneously via a proprietary functionalized nanoparticle system. Unlike first-generation crystalline single-drug balloons, SirPlux Duo enables active cellular uptake within the vessel wall and sustained local drug retention at lower doses. The technology is exclusively licensed from Cleveland Clinic and supported by first-in-human data across 28 patients with two-year follow-up showing no new treatment failures. Proceeds will support FDA IDE submissions for two coronary indications — in-stent restenosis and small-vessel de novo lesions — and a BTK early feasibility study.

Read the full announcement at PR Newswire →

Qaelon Medical and Scialytics AI surgical intelligence partnership

NEWS · MEDTECH · HCIT

EXTERNAL →

MedTechHCITDiagnostics

Qaelon Medical and Scialytics Announce Data Partnership to Advance AI-Driven Surgical Intelligence in Colorectal Surgery

Simon Jones, Deputy Editor · 3 June 2026

Qaelon Medical and Scialytics have announced a strategic non-exclusive partnership to integrate Qaelon's real-time physiologic gastrointestinal data into Scialytics' AI-driven surgical analytics platform, marking an important step toward objective, data-driven surgical intelligence in colorectal surgery. Anastomotic leaks — failure of the surgical connection following colorectal resection — occur in up to 19–21% of procedures and carry significant associated morbidity, mortality and healthcare costs. Today's detection and risk assessment methods remain subjective and non-standardised. Qaelon is converting a century-old visual air-leak test into an objective real-time digital physiologic signal, while Scialytics provides video-based AI analytics across the surgical workflow. The partnership aims to connect intraoperative performance with postoperative outcomes in a measurable, structured way. Qaelon's broader strategy is to build the first open-architecture gastrointestinal data ecosystem spanning pre-, intra- and post-operative care, with the Qaelon Objective Performance Indicator (OPI) serving as the foundational real-time signal layer.

Read the full announcement at PR Newswire →

John Slump launches Metis MedTech investment platform

NEWS · MEDTECH · INVESTMENT · M&A

EXTERNAL →

MedTechInvestmentM&A

Serial MedTech Founder John Slump Launches Metis MedTech Investment and Advisory Platform Following Atraverse Medical's Acquisition by Johnson & Johnson

Simon Jones, Deputy Editor · 28 May 2026

John Slump — co-founder and former President and CEO of Atraverse Medical — has launched Metis MedTech, an investment and strategic advisory platform for medical device founders, following the close of Johnson & Johnson's acquisition of Atraverse Medical on 15 May 2026. Slump brings a medtech operating track record across four medical device exits representing more than $1.25 billion in aggregate transaction value — including Farapulse (acquired by Boston Scientific, 2021), Surgical Innovation Associates (acquired by Integra LifeSciences, 2022), Attune Medical (acquired by Haemonetics, 2024) and Atraverse Medical. Metis MedTech provides aligned capital and operator-level partnership for medical device founders across financing, regulatory strategy and commercialisation — with recent investment and advisory activity including Field Medical, Madison Scientific and StimCardio Medical. Slump described the platform as combining founder-friendly investment capital with operating experience and strategic support, enabling teams to execute swiftly while preserving founder control.

Read the full announcement at PR Newswire →

Stay Ahead of UK Healthcare Investment News

Subscribe free for M&A deals, funding rounds and market intelligence across all nine UK healthcare sectors — including alternative healthcare investments, specialty pharma and medical cannabis.

Subscribe Free →